Agios Pharma (DE:8AP)
FRANKFURT:8AP
Holding DE:8AP?
Track your performance easily

Agios Pharma (8AP) Income Statement

0 Followers

Agios Pharma Income Statement

Last quarter (Q3 2024), Agios Pharma's total revenue was $8.96M, an increase of 21.15% from the same quarter last year. In Q3, Agios Pharma's net income was $947.91M. See Agios Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 32.87M$ 26.82M$ 14.24M$ 500.00K$ 203.20M$ 117.91M
Cost of Revenue
$ 3.49M$ 2.88M$ 1.70M-$ -2.81M$ 1.32M
Gross Profit
$ 29.38M$ 23.94M$ 12.54M$ 500.00K$ 200.39M$ 116.59M
Operating Expense
$ 436.36M$ 415.43M$ 401.58M$ 378.42M$ 335.92M$ 542.93M
Operating Income
$ -406.98M$ -391.49M$ -389.05M$ -378.42M$ -335.92M$ -426.33M
Net Non Operating Interest Income Expense
$ 55.04M$ 33.34M$ 12.79M$ 836.00K$ 6.61M$ 14.86M
Other Income Expense
$ -178.12M$ 6.05M$ 144.45M$ -21.07M$ -61.51M$ -31.61M
Pretax Income
$ 727.43M$ -352.09M$ -231.80M$ -356.51M$ -329.31M$ -411.47M
Tax Provision
$ 53.12M-----
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 674.31M$ -352.09M$ -231.80M$ 1.60B$ -327.37M$ -411.47M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 439.85M$ 418.31M$ 403.29M$ 378.42M$ 513.74M$ 544.25M
Net Income From Continuing And Discontinued Operation
$ 674.31M$ -352.09M$ -231.80M$ 1.60B$ -327.37M$ -411.47M
Normalized Income
$ 539.34M$ -278.15M----
Interest Expense
------
EBIT
$ -386.75M$ -391.49M$ -389.05M$ -378.42M$ -335.92M$ -411.47M
EBITDA
$ -375.41M$ -384.86M$ -380.48M$ -369.18M$ -326.13M$ -398.05M
Currency in USD

Agios Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis